FDA clears Opus Genetics IND for RDH12 childhood blindness therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. WCN
6. SPOT
7. BMY
8. FIX
9. TSCO
10. BE

Go back to FDA clears Opus Genetics IND for RDH12 childhood blindness therapy

Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness

October 21, 2026 7:00 AM EDT

FDA clearance enables clinical development of OPGx-RDH12 for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease that causes progressive vision loss beginning in early childhood

Strategic collaboration with the Global RDH12 Alliance supports the development of a potential treatment for this disease with high unmet need

RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq:... More